within Pharmacolibrary.Drugs.ATC.C;

model C02CC04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 1.6666666666666667,
    adminDuration  = 600,
    adminMass      = 0.01,
    adminCount     = 1,
    Vd             = 0.145,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Debrisoquine is a sympatholytic antihypertensive agent formerly used for the treatment of hypertension. It is recognized mostly for its use as a probe drug for CYP2D6 pharmacogenetic phenotyping. As of now, debrisoquine is rarely used clinically.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li>C J Timmer, J M Sitsen, L P Delbressine,Clinical pharmacokinetics of mirtazapine.,Clinical pharmacokinetics,2000<a href='https://pubmed.ncbi.nlm.nih.gov/10885584/'>https://pubmed.ncbi.nlm.nih.gov/10885584/</a></li><li>A E Balant-Gorgia, M Gex-Fabry, L P Balant,Clinical pharmacokinetics of clomipramine.,Clinical pharmacokinetics,1991<a href='https://pubmed.ncbi.nlm.nih.gov/2044329/'>https://pubmed.ncbi.nlm.nih.gov/2044329/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C02CC04;
